A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals HPV vaccine (580299) co-administered with Boostrix polio (dTpa-IPV) in healthy female subjects aged 10–18 years.

Trial Profile

A multicentre study to evaluate the immunogenicity and safety of GSK Biologicals HPV vaccine (580299) co-administered with Boostrix polio (dTpa-IPV) in healthy female subjects aged 10–18 years.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs DTaP poliovirus vaccine; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
  • Indications Cervical cancer; Diphtheria; Human papillomavirus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Feb 2010 Results published in the Journal of Adolescent Health.
    • 22 Sep 2008 Actual end date reported as July 2008 by ClinicalTrials.gov.
    • 22 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top